文献速递前列腺癌

前列腺癌根治术后全国长期生存估计

National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer.
PubMed 文献 · Urology · 2023-11-10

该回顾性研究纳入2005至2015年在美国退伍军人健康管理局接受前列腺癌根治术的21992例局限性前列腺癌患者,随访至2019年。5951例(27%)发生生化复发,其中677例(11%)发生转移;生化复发后10年累积转移发生率为20%,转移后10年总生存率为34%,全队列10年前列腺癌特异性生存率为94%。

要点

  • 21992例根治术后患者中5951例(27%)出现生化复发,其中677例(11%)发生转移。
  • 生化复发后10年累积转移发生率为20%,中位总生存14年、10年生存率70%。
  • 转移后中位总生存接近7年、10年总生存率34%;全队列10年前列腺癌特异性生存率94%。

核心结论

  • 在这一大型当代全国队列中,生化复发前列腺癌男性的生存长于历史队列,这些更新估计或可更可靠地反映当前结局。

研究设计与样本

  • 回顾性研究,纳入2005至2015年在美国退伍军人健康管理局接受前列腺癌根治术的局限性前列腺癌男性,随访至2019年。
  • 生化复发定义为前列腺特异性抗原≥0.2 ng/mL,并使用经自然语言处理编码的验证数据集识别新发转移性前列腺癌。

主要发现

  • 21992例接受前列腺癌根治术的男性中,5951例(27%)发生生化复发。
  • 生化复发男性中677例(11%)发生转移。
  • 生化复发后10年生化复发累积发生率为28%,生化复发后10年转移累积发生率为20%。
  • 生化复发后中位总生存为14年,10年生存率为70%。
  • 自转移时起中位总生存接近7年,10年总生存率为34%;全队列10年前列腺癌特异性生存率为94%。

临床怎么用

  • 作者认为,在患者咨询和设计临床研究时,这些更新估计或可更可靠地反映当前结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer. METHODS: We conducted a retrospective study of men with localized prostate cancer treated with radical prostatectomy from 2005 to 2015 with follow-up through 2019 in the Veterans Health Administration. We defined biochemical recurrence (BCR) as a prostate-specific antigen ≥0.2 ng/mL. We used a validated natural language processing encoded dataset to identify incident metastatic prostate cancer. We estimated overall survival from time of surgery, time of BCR, and time of first metastasis using the Kaplan-Meier method. We then estimated time from surgery to BCR, BCR to metastatic disease, and prostate-cancer-specific survival from various time points using cumulative incidence considering competing risk of death. RESULTS: Of 21,992 men undergoing radical prostatectomy, we identified 5951 (27%) who developed BCR. Of men with BCR, 677 (11%) developed metastases. We estimated the 10-year cumulative incidence of BCR and metastases after BCR were 28% and 20%, respectively. Median overall survival after BCR was 14years, with 10-year survival of 70%. From the time of metastasis, median overall survival approached 7years, with 10-year overall survival of 34%. Prostate cancer-specific survival for the entire cohort at 10years was 94%. CONCLUSION: In this large contemporary national cohort, survival for men with biochemically recurrent prostate cancer is longer than historical cohorts. When counseling patients and designing clinical studies, these updated estimates may serve as more reliable reflections of current outcomes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Stensland KD, Caram MEV, Herr DJ, et al. National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2023. PMID: 37951360. doi:10.1016/j.urology.2023.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。